Biotech Stock Roundup: AbbVie's HCV Treatment Approved, ImmunoGen Plunges on Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Dec 24, 8:48AM CST
Will Express Scripts' announcement regarding AbbVie's (ABBV) Viekira Pak lead to a pricing war in the hepatitis C virus (HCV) market?
BIIB: 340.89 (+5.13), VRTX: 115.15 (+1.40), CBST: 100.29 (-0.09), GILD: 91.29 (+1.84), ACHN: 13.06 (+1.22), IMGN: 5.90 (+0.13), ABBV: 66.21 (+1.86)
Roche Loses A Little Luster Before Year-End
Stephen Simpson, CFA - at Seeking Alpha - Mon Dec 22, 1:45PM CST
BIIB: 340.89 (+5.13), IMGN: 5.90 (+0.13)
ImmunoGen/Roche's Kadcyla Fails in Study, Shares Plunge - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 22, 1:44PM CST
ImmunoGen (IMGN) and partner Roche's Kadcyla failed to meet the primary endpoint in a phase III study conducted in HER2-positive metastatic breast cancer patients.
LCI: 42.29 (+1.79), IMGN: 5.90 (+0.13), BIOD: 1.36 (-0.04)
Immunogen (IMGN) Showing Signs Of A Dead Cat Bounce Today
at The Street - Mon Dec 22, 8:48AM CST
Trade-Ideas LLC identified Immunogen (IMGN) as a "dead cat bounce" (down big yesterday but up big today) candidate
IMGN: 5.90 (+0.13)
ImmunoGen, Inc. Appoints Richard J. Gregory, Ph.D. as EVP, Chief Scientific Officer; John M. Lambert, Ph.D. Named EVP, Distinguished Research Fellow
Business Wire - Mon Dec 22, 5:30AM CST
ImmunoGen, Inc. (NASDAQ: IMGN), a biotechnology company that develops targeted anticancer therapies using its antibody-drug conjugate (ADC) technology, today announced the appointment of Richard J. Gregory, Ph.D., as Executive Vice President, Research and Chief Scientific Officer (CSO), reporting to ImmunoGen President and CEO, Daniel Junius. Dr. Gregory will join the Company on January 5, 2015, at which time current CSO, John Lambert, Ph.D., will assume the position of Executive Vice President, Distinguished Research Fellow. Dr. Gregory brings to ImmunoGen deep scientific and research management experience, most recently serving as senior vice president and head of research for the Sanofi Genzyme Research & Development Center.
IMGN: 5.90 (+0.13)
Why ImmunoGen Inc. Stock Was Throttled
Sean Williams, The Motley Fool - Motley Fool - Fri Dec 19, 3:05PM CST
This article originally appeared as part of ongoing coverage in our premium Motley Fool Rule Breakers service... we hope you enjoy this complimentary peek! What: Shares of ImmunoGen , a biopharmaceutical company...
IMGN: 5.90 (+0.13)
Seeking Alpha's Biotech Weekly: A Merck Purchase, Spectacular Auspex, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Dec 19, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. What should the Seeking Alpha community be reading and writing about? Please leave...
SPHS: 0.46 (+0.02), ASPX: 49.93 (-0.10), MDVN: 99.23 (+1.23), CYCC: 0.69 (+0.01), OPK: 9.63 (+0.21), NLNK: 39.08 (+1.36), JUNO: 39.99 (+2.71), REGN: 400.12 (+6.07), MYGN: 36.50 (+0.28), PFE: 31.42 (-0.03), IMGN: 5.90 (+0.13), AMGN: 160.67 (+3.15), GSK: 42.85 (+0.11), BMY: 59.15 (-0.01), BLRX: 1.68 (-0.01), OREX: 5.98 (+0.01), DVA: 76.06 (+0.07), BLCM: 19.30 (+0.18), CBST: 100.29 (-0.09), GILD: 91.29 (+1.84), GERN: 3.06 (+0.05), MRK: 57.46 (+0.25), NVS: 93.91 (+0.66)
Stocks at Session Highs as Energy Sector Picks Up Steam
at The Street - Fri Dec 19, 2:04PM CST
Stocks are higher Friday, with the energy sector leading the S&P 500's gains.
KMI: 42.01 (+0.10), NKE: 96.29 (+0.32), BBRY: 10.67 (-0.13), IMGN: 5.90 (+0.13), PETX: 17.05 (+0.42), FINL: 22.79 (+0.17), SLB: 87.06 (-0.26), KMX: 67.61 (-0.15), APP: 1.06 (+0.01), RHT: 70.92 (+0.47), CVX: 113.47 (-0.48), XLE: 80.13 (-0.59), TNK: 4.74 (+0.04)
Juno Therapeutics IPO Caps Big Year In Biotech Deals
at Investor's Business Daily - Fri Dec 19, 11:47AM CST
Juno Therapeutics (JUNO) set a record as the most highly valued biotech IPO this year, with the stock jumping 62% as trading began Friday. The initial public offering raised $265 million, with the company selling 11 million shares at 24. Juno...
IMDZ: 34.96 (+0.78), BLCM: 19.30 (+0.18), KITE: 51.96 (+0.45), IMGN: 5.90 (+0.13), JUNO: 39.99 (+2.71)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Dec 19, 11:45AM CST
RBY: 0.91 (+0.01), FATE: 4.90 (+0.23), IMDZ: 34.96 (+0.78), RXII: 1.60 (unch), GLMD: 5.95 (+0.15), TBIO: 2.31 (-0.09), SIM: 10.11 (+0.34), PHMD: 1.46 (-0.03), IMGN: 5.90 (+0.13), PETX: 17.05 (+0.42), NQ: 4.32 (-0.36), OTIC: 32.26 (+0.65), VHC: 5.98 (-0.19), FINL: 22.79 (+0.17), BBLU: 1.15 (-0.03), TRXC: 2.79 (+0.03), BAS: 7.30 (-0.08), ENRJ: 2.43 (+0.03), TNK: 4.74 (+0.04)
Roche Drugs For Alzheimer's, Breast Cancer Disappoint
at Investor's Business Daily - Fri Dec 19, 10:31AM CST
Big Swiss pharma Roche (RHHBY) halted development of its Alzheimer's disease drug and reported mediocre results from a clinical trial of breast-cancer drug Kadcyla Friday, sending the stock down more than 6% in early trading on the stock market...
BIIB: 340.89 (+5.13), IMGN: 5.90 (+0.13), LLY: 70.16 (+0.42)
Cramer: ‘Downside’ to Biotech as ImmunoGen Stock Cut in Half
at The Street - Fri Dec 19, 9:46AM CST
TheStreet's Jim Cramer takes a look at Celgene's positive news, as well as the bad news that caused shares of ImmunoGen to be nearly cut in half.
BIIB: 340.89 (+5.13), ISIS: 59.49 (+1.88), GILD: 91.29 (+1.84), IMGN: 5.90 (+0.13), REGN: 400.12 (+6.07), CELG: 109.60 (+3.48)
ImmunoGen (IMGN) Stock Plummets to One-Year Low on Disappointing Breast Cancer Drug Results
at The Street - Fri Dec 19, 9:35AM CST
Shares of ImmunoGen (IMGN) plunged more than 50% to a 52-week low of $5.36 on Friday after poor results of its experimental breast cancer treatment.
IMGN: 5.90 (+0.13)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Dec 19, 8:11AM CST
KMX: 67.61 (-0.15), MOLG: 2.92 (+0.03), CERS: 6.49 (+0.29), OREX: 5.98 (+0.01), APP: 1.06 (+0.01), ISIS: 59.49 (+1.88), PIR: 15.33 (-0.11), BBRY: 10.67 (-0.13), IMGN: 5.90 (+0.13), FMD: 5.06 (unch), RHT: 70.92 (+0.47), PETX: 17.05 (+0.42), NVGN: 2.40 (-0.09), TRXC: 2.79 (+0.03), NQ: 4.32 (-0.36), FINL: 22.79 (+0.17), TNK: 4.74 (+0.04)
ImmunoGen tanks on Roche Phase 3 failure
Seeking Alpha - at Seeking Alpha - Fri Dec 19, 7:44AM CST
IMGN: 5.90 (+0.13)
ImmunoGen Reports Roche Has Provided an Update on the MARIANNE Trial
Business Wire - Fri Dec 19, 12:02AM CST
ImmunoGen, Inc. (NASDAQ: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today reported that Roche has announced top-line results of its Phase III MARIANNE study.
IMGN: 5.90 (+0.13)
ImmunoGen, Inc. Announces Webcast of Presentation at the 33rd Annual J.P. Morgan Healthcare Conference
Business Wire - Mon Dec 15, 11:45AM CST
ImmunoGen, Inc. (NASDAQ: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that Daniel Junius, President and CEO, will present at the upcoming 33rd Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation is scheduled for 9:00 am PT (12:00 pm ET) on January 13, 2015.
JPM: 62.48 (unch), IMGN: 5.90 (+0.13)
Lilly maxes its cancer licenses under agreement with ImmunoGen
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 9:36AM CST
IMGN: 5.90 (+0.13), LLY: 70.16 (+0.42)
ImmunoGen Reports Encouraging Data on Cancer Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 08, 3:30PM CST
ImmunoGen (IMGN) presented encouraging data on IMGN529, being evaluated for the treatment of diffuse large B-cell lymphoma and other non-Hodgkin lymphoma subtypes.
IMGN: 5.90 (+0.13), AMGN: 160.67 (+3.15), SNY: 46.35 (+0.50)
ImmunoGen, Inc. Announces Encouraging IMGN529 Clinical Data Presented at 56th ASH Annual Meeting and Exposition
Business Wire - Sat Dec 06, 11:01AM CST
--Dose finding is ongoing, with the maximum tolerated dose (MTD) not yet established.
IMGN: 5.90 (+0.13)